Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates
- PMID: 16221544
- DOI: 10.1016/j.ejpb.2005.08.008
Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates
Abstract
Aggregation is one of the important issues encountered during the development of immunoglobulin-based drugs. The aim of the current review is to discuss the causes and consequences of immunoglobulin aggregation as well as the relevance of immunoglobulin aggregation to disease pathogenesis. Extracellular deposition of immunoglobulins, either monoclonal light chains or intact polyclonal antibodies, induces renal failure in various nephropathies. The aggregates can present fibrillar or amorphous structures. In this review, factors known to influence protein aggregation, such as the primary structure of the protein, local environment and glycosylation are assessed, as well as the subsequent altered clearance, fibril formation and toxicity. The role of the protein local environment is emphasized. Even if the local environment causes only minor perturbations in the protein structure, these perturbations might be sufficient to trigger aggregate formation. This fact underlines the importance of choosing appropriate formulations for protein drugs. If the formulation provides a slightly destabilizing environment to the protein, the long-term stability of the drug may be compromised by aggregate formation.
Similar articles
-
Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease.Hematol Oncol Clin North Am. 1992 Apr;6(2):323-46. Hematol Oncol Clin North Am. 1992. PMID: 1582976 Review.
-
Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.J Mol Biol. 2001 Nov 9;313(5):1021-34. doi: 10.1006/jmbi.2001.5092. J Mol Biol. 2001. PMID: 11700059
-
The role of lipid-protein interactions in amyloid-type protein fibril formation.Chem Phys Lipids. 2006 Jun;141(1-2):72-82. doi: 10.1016/j.chemphyslip.2006.02.006. Epub 2006 Mar 10. Chem Phys Lipids. 2006. PMID: 16569401 Review.
-
Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.Eur J Pharm Biopharm. 2007 Jan;65(1):1-9. doi: 10.1016/j.ejpb.2006.08.014. Epub 2006 Sep 1. Eur J Pharm Biopharm. 2007. PMID: 17034996
-
Renal amyloidosis (part I).J Nephrol. 2006 Mar-Apr;19(2):123-5. J Nephrol. 2006. PMID: 16736407
Cited by
-
Heavy-chain deposition disease: a morphological, immunofluorescence and ultrastructural assessment.Clin Kidney J. 2012 Oct;5(5):383-9. doi: 10.1093/ckj/sfs062. Clin Kidney J. 2012. PMID: 26019812 Free PMC article.
-
Sunset Yellow Dye Induces Amorphous Aggregation in β-Lactoglobulin at Acidic pH: A Multi-Techniques Approach.Polymers (Basel). 2022 Jan 20;14(3):395. doi: 10.3390/polym14030395. Polymers (Basel). 2022. PMID: 35160385 Free PMC article.
-
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.J Biol Chem. 2012 Jul 20;287(30):25266-79. doi: 10.1074/jbc.M111.330902. Epub 2012 May 14. J Biol Chem. 2012. PMID: 22584577 Free PMC article.
-
Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.Blood. 2008 Sep 1;112(5):1931-41. doi: 10.1182/blood-2008-03-143040. Epub 2008 Jun 20. Blood. 2008. PMID: 18567838 Free PMC article.
-
Synthesis of Disulfide-Bridging Trehalose Polymers for Antibody and Fab Conjugation Using a Bis-Sulfone ATRP Initiator.Polym Chem. 2021 Mar 7;12(9):1217-1223. doi: 10.1039/d0py01579b. Epub 2021 Feb 11. Polym Chem. 2021. PMID: 34211593 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical